Bavarian Nordic initiated process to identify new CEO

Bavarian Nordic initiated process to identify new CEO

Bavarian Nordic Announces Leadership Transition Amid Shareholder Uncertainty

Bavarian Nordic A/S (OMX: BAVA) has confirmed a leadership transition following the collapse of a proposed private equity takeover in late 2025. Luc Debruyne, who served as chair of the board since early 2023, stepped down immediately after the failed acquisition attempt by Nordic Capital and Permira, which secured only 60% shareholder approval. The board appointed Anne Louise Eberhard, previously vice chair, as the new chair to ensure governance stability according to company announcement.

The failed buyout, initially valued at 250 Danish kroner ($38.61) per share, faced opposition from major shareholder ATP, Denmark's largest pension fund, which criticized the timing and valuation. Despite the board's unanimous endorsement of the deal, insufficient shareholder support left the company's shares trading at 187 kroner as of November 13, 2025 according to financial reporting.

While the company has not explicitly stated plans to replace its current CEO, Paul Chaplin, who has led Bavarian Nordic since 2014, the board's focus on "continued execution of the strategy" suggests a potential review of leadership structures in the coming months as reported by the company. Eberhard emphasized the board's commitment to maintaining stability and collaborating with management to advance the company's growth trajectory, particularly in its vaccine portfolio for public health preparedness and travel immunizations according to official statements.

The leadership shift occurs amid broader turbulence in Danish pharmaceutical governance, including recent board changes at Novo Nordisk as noted in industry coverage. Bavarian Nordic's shares, which closed at 187 kroner on March 2, 2026, reflect ongoing investor uncertainty about the company's strategic direction post-takeover attempt.

The board has invited shareholder dialogue ahead of the 2026 annual general meeting, signaling openness to feedback on future governance and leadership decisions. No further details on CEO succession plans have been disclosed at this time.

(https://www.fiercepharma.com/pharma/bavarian-nordic-board-chair-exits-immediately-aftermath-failed-private-equity-takeover): Bavarian Nordic board chair exits in aftermath of failed private equity takeover
(https://www.bavarian-nordic.com/investor/news/news.aspx?news=7378): Bavarian Nordic Announces Changes to the Board
(https://www.bavarian-nordic.com/about/leadership.aspx): Bavarian Nordic Management Profiles